cro.directory
← Compare landing

Aragen Life Sciences vs ProBio

Auto-generated comparison by BioBM Editorial AI. This page highlights available profile evidence side by side and avoids drawing conclusions from missing fields.

Markdown mirror: /api/markdown/compare/aragen/probio

CategoryAragen Life SciencesProBio
Listed sitecroboth
SummaryGlobal CRDMO partner offering integrated discovery-to-commercialization services across small molecules and biologics, with 4000+ scientists and R&D/manufacturing campuses in Asia, North America, and Europe.ProBio is a leading global CDMO subsidiary of GenScript Biotech Corporation, providing end-to-end services for biologics and cell & gene therapy (CGT) from drug discovery through commercialization.
Services
  • Discovery Research
  • Target Identification & Validation
  • High-Throughput Screening
  • Medicinal Chemistry
  • Computational & In-Silico Drug Discovery
  • Protein Engineering
  • In Vitro Pharmacology
  • In Vitro ADME / DMPK
  • Safety Pharmacology
  • Genetic Toxicology
  • Preclinical In Vitro Studies
  • Preclinical In Vivo Studies
  • In Vivo Efficacy Models
  • In Vivo PK / PD Studies
  • GLP Toxicology
  • Carcinogenicity Studies
  • DART (Reproductive & Developmental Toxicology)
  • Specialized & Large-Animal Models
  • Bioanalysis
  • LC-MS Bioanalysis (Small Molecule)
  • Ligand-Binding Bioanalysis (Large Molecule)
  • Immunogenicity Assays (ADA / NAb)
  • Biomarker Assays
  • Flow Cytometry Services
  • Analytical Method Development & Validation
  • ICH Stability Studies
  • Translational Research
  • US FDA Regulatory Strategy
  • EU EMA Regulatory Strategy
  • Japan PMDA Regulatory Strategy
  • China NMPA Regulatory Strategy
  • Regulatory Affairs
  • Analytical Method Development & Validation
  • ICH Stability Studies
  • In Vitro Pharmacology
  • Protein Engineering
  • Bioanalysis
  • Flow Cytometry Services
  • Immunogenicity Assays (ADA / NAb)
Modalities
  • Small Molecule
  • Biologics (Monoclonal Antibodies)
  • Biologics (Other)
  • Antibody-Drug Conjugate (ADC)
  • Oligonucleotide
  • mRNA
  • Cell Therapy
  • Gene Therapy
  • Peptide
  • Vaccine
  • Biologics (Monoclonal Antibodies)
  • Biologics (Other)
  • mRNA
  • Cell Therapy
  • Gene Therapy
  • Vaccine
  • AAV / Viral Vector Platform
Indications
  • Oncology
  • Immunology
  • Neurology
  • Psychiatry
  • Metabolic
  • Cardiovascular
  • Infectious Disease
  • Rare Disease
  • Respiratory
  • Dermatology
  • Ophthalmology
  • Gastroenterology
  • Nephrology
  • Women's Health
  • Infectious Disease
Locations
  • Global Headquarters, Hyderabad, Telangana, India
  • R&D and Manufacturing Campus, Hyderabad, Telangana, India
  • R&D Campus, Hyderabad, Telangana, India
  • Manufacturing Campus, Visakhapatnam, Andhra Pradesh, India
  • R&D Campus, Bengaluru, Karnataka, India
  • Biosafety Solutions, Pune, Maharashtra, India
  • Regional Office, New Delhi, Delhi, India
  • Sales Office, Tokyo, Japan
  • Sales Office, Seoul, South Korea
  • Sales Office, Cambridge, Massachusetts, USA
  • R&D Campus, Morgan Hill, California, USA
  • Sales Office, Utrecht, Netherlands
  • Sales Office, Milan, Italy
  • Sales Office, South Korea
  • Global Headquarters & R&D and Manufacturing Campus, Hyderabad, Telangana, India
  • R&D Campus, Pune, Maharashtra, India
  • R&D Campus, New Delhi, Delhi, India
  • Sales Office, New Jersey, New Jersey, USA
  • Global Headquarters, R&D and Manufacturing Campus, Hyderabad, Telangana, India
  • R&D Campus, Mallapur, Hyderabad, India
  • United States, United States
  • Netherlands, Netherlands
  • South Korea, South Korea
  • Hong Kong, Hong Kong, China
  • Shanghai, Shanghai, China
  • Nanjing, Nanjing, China
Certifications
  • USFDA · Identifier: EIR for Nacharam Unit 1
  • FDA · Identifier: US Food and Drug Administration
  • EMA · Identifier: European Medicines Agency
  • NMPA · Identifier: National Medical Products Administration
ReviewsReview summary appears after site-level review signal gate opens.Review summary appears after site-level review signal gate opens.